Intas Pharma inks licensing agreement with Korean firm to develop new products
Intas Pharma inks licensing agreement with Korean firm to develop new products Intas Pharma inks licensing agreement with Korean firm to develop new products 08 January 2021 | News Alteogen will receive an initial payment of $6 million and is also eligible to receive additional milestones upon Intas’ achievement of specified development, regulatory and sales milestones, totalling up to $109 million Source credit: Shutterstock South Korean firm Alteogen Inc has announced that it has entered into an exclusive license agreement with Ahmedabad based Intas Pharmaceuticals Ltd to use ALT...
Source: biospectrumindia.com